Furui Co.,Ltd(SZ:300049) Guoxin Securities·2025-08-26 02:53Investment Rating - The investment rating for the company is "Outperform the Market" [5][21]. Core Views - The company reported a revenue growth of 20% year-on-year in Q2 2025, with a significant catalyst from the MASH non-invasive testing [1][3]. - The revenue for the first half of 2025 reached 713 million yuan, an increase of 11.02%, while the net profit attributable to the parent company was 52 million yuan, a decrease of 31.09% [1][6]. - The approval of the MASH drug by the FDA is expected to drive demand for non-invasive liver disease testing, positioning the company as a leader in this market [3][19]. Financial Performance - The company achieved a revenue of 383 million yuan in Q2 2025, reflecting a growth of 19.76% [1][6]. - The pharmaceutical and medical services segment generated revenue of 231 million yuan, up 5.62%, while the medical device segment saw a revenue increase of 13.80%, totaling 480 million yuan [2][12]. - The gross margin for the first half of 2025 was 75.26%, a slight decrease of 1.03 percentage points, primarily due to changes in business structure [2][16]. Profitability Forecast - The company forecasts revenues of 1.63 billion yuan, 1.92 billion yuan, and 2.27 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 21%, 18%, and 18% [3][4]. - The net profit attributable to the parent company is expected to reach 210 million yuan, 280 million yuan, and 360 million yuan for the same years, with growth rates of 83%, 35%, and 29% [3][4]. Market Position - The company has established a strong market presence with its FibroScan product line, which is recognized globally and has received various certifications [3][19]. - The company has installed 977 units of its FibroScan products worldwide, indicating robust market penetration [2][12].